US signs $1 billion deal for COVID-19 antibody drug
The treament, developed by GSK and Vir Biotechnology, has shown to cut the risk of hospitalization or death by 79% in adults with mild-to-moderate COVID-19.
A health worker holds up a vial of Imdevimab, an antibody cocktail designed to produce resistance to the coronavirus disease (COVID-19), at San Giuseppe Hospital, in Albano, Italy, April 22, 2021(photo credit: REUTERS/YARA NARDI)ByREUTERSUpdated:
